Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.
Standard
Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. / Tribius, Silke; Ihloff, Anna-Sophie; Rieckmann, Thorsten; Petersen, Cordula; Hoffmann, Markus.
in: CANCER LETT, Jahrgang 304, Nr. 2, 2, 2011, S. 71-79.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know.
AU - Tribius, Silke
AU - Ihloff, Anna-Sophie
AU - Rieckmann, Thorsten
AU - Petersen, Cordula
AU - Hoffmann, Markus
PY - 2011
Y1 - 2011
N2 - Studies report an increasing incidence of oropharyngeal cancers linked to infection by human papillomavirus (HPV). We reviewed trials assessing outcomes by HPV DNA status in patients with locally advanced oropharyngeal cancer. Seven of the eight studies identified showed significantly better survival in patients with HPV DNA-positive tumors vs. HPV DNA-negative tumors. The review also describes what needs to be defined regarding optimal treatments. Future trials should incorporate HPV DNA status as a risk determinant and explore treatments for high-risk patients needing therapy intensification, and low- and intermediate-risk patients needing treatment de-intensification to improve tolerability, without compromising survival.
AB - Studies report an increasing incidence of oropharyngeal cancers linked to infection by human papillomavirus (HPV). We reviewed trials assessing outcomes by HPV DNA status in patients with locally advanced oropharyngeal cancer. Seven of the eight studies identified showed significantly better survival in patients with HPV DNA-positive tumors vs. HPV DNA-negative tumors. The review also describes what needs to be defined regarding optimal treatments. Future trials should incorporate HPV DNA status as a risk determinant and explore treatments for high-risk patients needing therapy intensification, and low- and intermediate-risk patients needing treatment de-intensification to improve tolerability, without compromising survival.
M3 - SCORING: Journal article
VL - 304
SP - 71
EP - 79
JO - CANCER LETT
JF - CANCER LETT
SN - 0304-3835
IS - 2
M1 - 2
ER -